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Abstract Systemic sclerosis (SSc) is an autoimmune
disease characterized by vasculopathy, immune cell activa-
tion, and fibrosis of the skin and internal organs. Over the
past few years,a role forgenetics inthesusceptibilityfor SSc
has been established. This review aims to provide an update
on the progress made in the past year or so within the field of
SSc genetics research. This year has been of particular
interest due to the publication of a large genome-wide
association study, further investigations into gene–gene
interactions, and the tendency to validate genetic results in
functional models.
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Introduction
Systemic sclerosis (SSc) is a multifaceted autoimmune
disease. Its main manifestations are vasculopathy, immune
activation, and ultimately extensive fibrosis of the skin and
internal organs [1]. Until recently, the precise pathogenesis
had not been elucidated, despite the growing interest and
efforts from the scientific community in unraveling the
factors involved in SSc susceptibility. Over the years, it has
been suggested that environmental as well as genetic risk
factors predispose individuals to the onset of SSc [2, 3].
Environmental factors are likely to play a role in triggering
disease because genetics does not provide a full justification
forthedevelopmentofSSc.However,reportsonpredisposing
environmental factors are ambiguous, and meta-analyses are
severely hindered by differences in the methodologies used
for exposure measurement by individual studies [4], which
unfortunately leaves a convincing environmental risk factor
to be discovered. Despite the difficulties involved with
composing large, clinically well-defined cohorts, genetic
research was able to discover multiple genetic risk factors
that have been replicated or challenged by other studies.
Many small and underpowered studies scrutinizing genetic
risk factors were published in an earlier period, but thanks to
the remarkable evolution of genetic research, SSc genetic
cohorts and the genetic analyses performed became more
comprehensive. Extensive reviews of these small studies and
other findings in the field of genetic research throughout
history have been published recently [5]. The aim of this
review is to provide an update on the key findings emerging
from studies from the past year that have explored the
genetic background of SSc.
Family Studies
Although SSc is not inherited in a mendelian fashion, the
highest risk factor for developing SSc today remains having
a sibling (15- to 19-fold increase) or other first-degree
relative (13- to 15-fold increase) with SSc. It must be noted
that the relative risk (RR) of developing SSc remains rather
low: 1.6% in families versus 0.026% in the general
population [6, 7]. In 2010, these findings were further
substantiated by a study investigating the heritability of SSc
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DOI 10.1007/s11926-011-0221-7in relation to Raynaud’s phenomenon (RP), other autoim-
mune disease (AID), and fibrotic interstitial lung disease
[8]. This study utilized a very powerful genealogic
resource, the Utah Population Database, which contains
both family structure data and medical records from more
than 7 million individuals. The genetic structure of Utah
residents is most similar to descendants from Northern
Europe in that very low inbreeding rates are present. The
cohort harbored 1,316 unique SSc patients, 1,037 of whom
had a child and/or a parent and hence could be included in
the study. For each SSc patient, 10 age-, gender-, and place
of birth–matched healthy controls were randomly selected.
From these 1,037 individuals, 50 families were identified
that had a significantly larger than expected number of SSc
cases. In these families, the RR ranged from 3.07 (95% CI,
1.25–7.57) in first-degree relatives to 2.14 (95% CI, 1.16–
3.95) in third-degree relatives. In fourth-degree relatives, no
significantly increased risk was present. An additional
prerequisite of this study was that it included the heritability
of RP among relatives of individuals with SSc. The study
found a significant increase in RP risk in first- and second-
degree relatives (RR, 6.38 [95% CI, 3.44–11.83] and 2.39
[95% CI, 1.21–4.74], respectively). The results concerning
fibrotic disease heritability were somewhat less straightfor-
ward, as first- to fourth-degree relatives all had a significantly
increased risk of developing interstitial lung disease, except
the second-degree relatives. The authors did not provide a
clear explanation for this observation but stated that the
analysis may be limited by the selection of only interstitial
lung disease as an outcome for inheritance of fibrosing
disease,excluding,forinstance,morpheaandbiliarycirrhosis.
The third result presented in this study—the increased
prevalence of other AIDs in families with SSc—matches the
results of another study published in 2010 [9]. This study
described a markedly increased prevalence of systemic lupus
erythematosus (SLE) in North American families from 1,071
SSc probands (OR, 16.98 [95% CI, 1.02–227.82]). To a
lesser extent, hypothyroidism (OR, 2.51 [95% CI, 1.46–
4.62]) and hyperthyroidism (OR, 2.76 [95% CI, 1.16–7.97])
were found to have an increased prevalence in these families.
The Achilles heel of this kind of study is the validation of
family-derived data. The study conducted in Utah based the
identification of cases on billing codes. Unfortunately, the
data used were de-identified, so no independent validation
could be carried out. In addition, the authors noted that not
all SSc patients had a record of RP, which is generally
considered to be almost universally present in SSc. Cases in
the second study were well-ascertained by chart review or
interviews of all first-degree relatives with reported AID by
the same rheumatologist. Intriguingly, a study comparing
987 SSc cases with their 3,088 unaffected siblings found that
the risk of developing SSc increased with increasing order of
birth and number of pregnancies, suggesting that immune
development very soon after birth or during pregnancy plays
a role in SSc development [10￿]. These findings might be the
start of the unveiling of an apparent role for (epigenetic)
imprinting and may wipe the dust from older studies
describing a role for microchimerism in SSc [11].
Candidate Gene Studies
Over the past few years, several single nucleotide poly-
morphisms (SNPs) have been found to be enriched in
patients with SSc or its clinical phenotypes compared with
healthy controls. The SNPs were usually selected based on
their locusinagenelikelytobeinvolvedinSSc pathogenesis,
or when the SNP already posed a risk to another AID. Using
these strategies, several novel genetic risk factors were
identified. Herein we review new insights into the role of
established candidate genes and describe novel associations.
We focus on studies of sufficient size and power or findings
that are, in our opinion, of special interest. In the last
paragraph of this section, we briefly highlight some well-
designedstudieswithnegativeresults,whichfortunatelyseem
to be accepted for publication more frequently in recent
years, counterbalancing positive publication bias. Table 1
displays the effect sizes and summarizes the results of the
studies described below.
STAT4
After the discovery that signal transducer and activator of
transcription 4 (STAT4) polymorphisms play a role in
rheumatoid arthritis (RA) and SLE susceptibility [12], a
role for this gene in SSc susceptibility was found as well.
An initial study in 1,317 SSc patients and 3,113 healthy
controls found the STAT4 rs7574865 T allele to be
associated with limited cutaneous SSc (lcSSc), but not with
diffuse cutaneous SSc (dcSSC) [13]. The same association
was substantiated in a Japanese cohort [14]. Subsequently,
two other studies corroborated these results and strongly
implicated STAT4 in SSc susceptibility [15, 16]. Last year,
these results prompted a combined European effort to
investigate the functional role of the STAT4 gene in mice.
Both STAT4-deficient wild-type mice were injected with
bleomycin. STAT4 knockout mice had a decreased T-cell
activation, proliferation, and cytokine release, which led to
less fibrosis. Of interest, STAT4-deficient Tsk1 mice (a well-
recognized murine SSc model) did not have a more severe
fibrotic phenotype. From these observations, the authors
drew the conclusion that STAT4 is intricately involved in
fibrosis and activation of fibroblasts. However, it must be
noted that STAT4 is a T-helper type 1 (Th1) promoter as well;
therefore, a more straightforward explanation might be that
STAT4-deficient mice have fewer Th1 circulating cells and
12 Curr Rheumatol Rep (2012) 14:11–21Table 1 Newly described non-HLA susceptibility genes for SSc and its clinical phenotypes
Gene SNP (associated allele/genotype) Association Population Size (tested phenotype/HC) OR (95% CI) Reference
TNFSF4 rs2205960 (T allele) SSc US 1,059/698 1.2 (1.1–1.5) [19]
ATA
+ US 174/698 1.4 (1.1–1.9) [19]
rs1234314 (G allele) SSc US 1,059/698 1.2 (1.04–1.4) [19]
ACA
+ US 300/698 1.3 (1.1–1.6) [19]
ATA
+ US 174/698 1.3 (1.02–1.7) [19]
SSc European 2,856/2,920 1.15 (1.02–1.31) [20]
lcSSc European 1,608/2,920 1.22 (1.07–1.38) [20]
ACA
+ European 828/2,920 1.23 (1.10–1.37) [20]
rs844648 (A allele) SSc US 1,059/698 0.8 (0.7–0.97) [19]
ATA
+ US 193/698 1.4 (1.1–1.8) [19]
lcSSc European 1,673/2,977 1.1 (1.01–1.20) [20]
ACA
+ European 860/2,977 1.12 (1.01–1.25) [20]
rs844644 (A allele) lcSSc European 1,653/2,946 0.91 (0.83–0.99) [20]
ACA
+ European 856/2,912 0.90 (0.80–1.00) [20]
rs12039904 (T allele) SSc European 2,894/2,991 1.18 (1.08–1.29) [20]
lcSSc European 1,639/2,991 1.20 (1.09–1.33) [20]
ACA
+ European 840/2,991 1.22 (1.07–1.38) [20]
BLK rs2736340 (TT genotype) SSc European and US 1,639/1,416 1.71 (1.2–2.4) [22]
ACA
+ European and US 510/1,416 2.27 (1.5–3.5) [22]
rs2736340 (CT genotype) SSc European and US 1,639/1,416 1.31 (1.1–1.5) [22]
ACA
+ European and US 510/1,416 1.6 (1.2–2.0) [22]
rs13277113 (AA genotype) SSc European and US 1,639/1,416 1.25 (1.1–1.4) [22]
ACA
+ European and US 510/1,416 1.42 (1.2–1.7) [22]
rs13277113 (A allele) SSc Japanese 309/769 1.45 (1.17–1.79) [22]
TNFAIP3 rs5029939 (T allele) SSc European 1,667/1,318 2.08 (1.59–2.72) [25]
dcSSc European 523/1,318 2.71 (1.94–3.79) [25]
FA European 532/1,318 2.26 (1.61–3.17) [25]
PAH European 119/1,318 3.11 (1.86–5.17) [25]
KCNA5 rs10744676 (C allele) PAH European 192/1,008 0.36 (0.21–0.63) [27]
PTPN22 rs2476601 (T allele) SSc European and US 3,422/3,638 1.15 (1.03–1.28) [32]
ACA
+ European and US 1,376/4,126 1.22 (1.05–1.42) [32]
NLRP1 rs8182352 (C allele) FA European 674/1,587 1.19 (1.05–1.36) [34]
ATA
+ European 536/1,587 1.23 (1.07–1.41) [34]
HGF HGF −1652 (TT genotype) ESLD Japanese 30/268 8.1 (2.5–26.0) [36￿]
CD226 rs763361 (T allele) SSc European 1,990/1,642 1.22 (1.10–1.34) [39]
rs763361 (TT genotype) dcSSc European 600/1,642 1.86 (1.42–2.43) [39]
FA European 662/1,642 1.82 (1.38–2.40) [39]
ATA
+ European 553/1,642 1.61 (1.25–2.08) [39]
CD247 rs2056626 (G allele) SSc European and US 5,049/9,740 0.85 (0.81–0.89) [47￿]
SSc French 1,031/1,014 0.78 (0.68–0.88) [49]
dcSSc French 308/1,014 0.79 (0.65–0.95) [49]
lcSSc French 643/1,014 0.79 (0.69–0.92) [49]
FA French 346/1,014 0.78 (0.65–0.93) [49]
IRF8 rs11642873 (A allele) lcSSc European and US 3,360/10,143 0.75 (0.69–0.81) [50￿]
GRB10 rs12540874 (A allele) lcSSc European and US 3,360/10,143 1.15 (1.09–1.22) [50￿]
SOX5 rs11047102 (C allele) ACA
+ European and US 1,791/10,143 1.36 (1.21–1.52) [50￿]
TNIP1 rs2233287 (A allele) SSc European 2,246/4,684 1.31 (1.15–1.43) [51]
RHOB rs13021401 (T allele) SSc European 2,246/4,684 1.21 (1.12–1.31) [51]
ACA anticentromere antibody; ATA antitopoisomerase antibody; dcSSc diffuse cutaneous systemic sclerosis; ESLD end-stage lung disease; FA
fibrosing alveolitis; HC healthy controls; lcSSc limited cutaneous systemic sclerosis; PAH pulmonary arterial hypertension; SNP single nucleotide
polymorphism SSc systemic sclerosis
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wild-type mice—something the authors did not address
[17￿]. Consequently, these results might be coming from an
overall impaired immune system rather than specifically less
fibrotic potential, as the authors state. In addition, SSc
patients carry an SNP in the gene that probably has a less
pronounced effect on the gene function than a complete
deletion of the gene, complicating translation of findings in
mice to human patients. More subtle approaches, such as
making use of immune cells from carriers of this particular
variant, are welcome to better gauge the precise implication
of this polymorphism in SSc.
OX40L
Tumor necrosis factor superfamily-4 (TNFSF4 or OX40
ligand [OX40L]) is the natural ligand of OX40, which is
present on T cells and influences T-cell survival and
expansion. OX40L binding partner OX40 is more highly
expressed in the serum of SSc patients than in healthy
controls. Moreover, polymorphisms in this gene have been
associated with SLE previously [18]. An initial American
cohort consisting of 1,059 Caucasian SSc cases and 698
healthy controls found the rare variants of SNPs rs2205960,
rs1234314, and rs844648 to be associated with SSc
susceptibility. Additional analysis of clinical phenotypes
demonstrated significant associations of OX40L variants
with lcSSc and dcSSC, as well as antitopoisomerase
antibody (ATA) and anticentromere antibody (ACA) pro-
files [19]. These results were recently corroborated by a
European effort investigating the influence of TNFSF4
polymorphisms in SSc susceptibility. This study found the
most marked associations in patients with lcSSc and ACAs.
In addition, this study identified novel OX40L haplotypes
involved in SSc susceptibility [20].
The FAM167A-BLK Region
The FAM167A-BLK region, previously known as C8orf13-
BLK, has been associated with multiple immune diseases
[21]. In 2010, two studies addressing two polymorphisms
in this region, rs13277113 and rs2736340, found an
association with lcSSc and dcSSc. The T allelle of
rs2736340 was associated with SSc in both a US and
a Spanish case–control population [22]. Both variants
were enriched in patients with ACAs and lcSSc in a
combined analysis. A role for the rs13277113 variant in
SSc was further substantiated by a Japanese study, which
did not investigate rs2736340 [23]. Moreover, RNA
expression profiling using peripheral blood elucidated
significantly differentially expressed genes in the B-cell
receptor–signaling pathways between patients with
different genotypes [22].
TNFAIP3
Tumor necrosis factor-α–induced protein 3 (TNFAIP3)i sa
cytoplasmic zinc finger protein that inhibits nuclear
factor-κB activity and tumor necrosis factor–mediated
programmed cell death. Polymorphisms in this gene have
been repeatedly associated with AID susceptibility [24].
A European study investigated 3 SNPs in 1,018 French
patients with SSc and 1,012 French Caucasian controls.
The TNFAIP3 rs5029939 was found to be associated with
SSc and subsequently replicated in a second set of 649
patients and 306 controls of German and Italian descent
(OR, 2.08 [95% CI, 1.59–2.72]). In addition, the strongest
association of rs5029939 was observed for dcSSc (OR,
2.71 [95% CI, 1.94–3.79]), fibrosing alveolitis (OR, 2.26
[95% CI, 1.61–3.17]), and pulmonary arterial hypertension
(PAH) (OR, 3.11 [95% CI, 1.86–5.17]) [25].
KCNA5
Based on the observations of potassium voltage-gated
channel, shaker-related subfamily, member 5 (KCNA5)
polymorphisms contributing to idiopathic pulmonary hyper-
tension, a study was initiated in 638 SSc patients and 469
controls to determine whether KCNA5 polymorphisms confer
susceptibility to SSc and, more specifically, to PAH [26].
Four KCNA5 SNPs were genotyped, from which the
rs10744676 variant was found to be associated with SSc
(OR, 0.62 [95% CI, 0.48–0.79]). In addition, this polymor-
phism influenced SSc-related PAH (OR, 0.31 [95% CI,
0.13–0.71]). Subsequently, the results were replicated in 938
SSc patients and 564 controls. The above association with
PAH in SSc was replicated, but not the association with SSc
overall. However, some care must be taken with interpreta-
tion of these results because this study did not only include
patients diagnosed with PAH on the basis of right heart
catheterization, but also included those with PAH based on
isolated diffusing capacity of the lung for carbon monoxide
less than 50% predicted, and with unexplained dyspnea [27].
PTPN22
Protein tyrosine phosphatase non-receptor 22 (PTPN22) has
been found to be associated with a broad array of AIDs,
including RA and SLE [28]. Although not fully conclusive,
a role for the PTPN22 R620W polymorphism has been
evaluated in SSc multiple times [29–31]. This year, a study
was published again addressing the role of this variant but
also the role of a novel described PTPN22 variant in SSc
susceptibility. In total, 3,422 SSc patients and 3,638 healthy
controls from 7 different ethnic cohorts were included in
this study. The meta-analysis performed in these cohorts
identified the rs2476601 T allele as a risk factor for SSc
14 Curr Rheumatol Rep (2012) 14:11–21susceptibility (OR, 1.15 [95% CI, 1.03–1.28]). Moreover,
the rs2476601 T allele was significantly associated with
ACAs (OR, 1.22 [95% CI, 1.05–1.42]). The study suggests
that the PTPN22 R620W polymorphism influences SSc
genetic susceptibility, whereas the novel R263Q genetic
variant does not [32].
NLRP1
Based on the idea that T cells are able to dampen the
inflammasome through NLRP1 responses and the observa-
tion that NLRP1 variants were found to confer susceptibility
to AIDs, an endeavor was initiated to investigate this gene in
SSc [33]. This study focused on 5 polymorphisms in a
discovery set composed of 870 SSc patients and 962 controls
and a German and Italian replication set consisting of 1,060
SSc patients and 625 controls. The discovery cohort revealed
a significant association for the NLRP1 rs8182352 variant
with both ATAs and fibrosing alveolitis. In the replication
cohort, no association was detected in the German popula-
tion. However, the association with ATAs was replicated in
the Italian population. When a meta-analysis was performed
considering an additive model for the rs8182352 SNP, the
investigators found this variant to confer susceptibility to
ATAs and fibrosing alveolitis under an additive model (OR,
1.23 [95% CI, 1.07–1.41] and 1.19 [95% CI, 1.05–1.35],
respectively). In addition, logistic regression analysis
showed an additive effect of IRF5 rs2004640, STAT4
rs7574865, and NLRP1 rs8182352 risk alleles on SSc-related
fibrosing alveolitis [34]. Although the authors state that
NLRP1 is a new genetic susceptibility factor for SSc-related
pulmonary fibrosis and ATA-positive SSc, this study would
benefit from an independent replication study. As the results
coming from the replication cohort are not straightforward, it
would be interesting to know the pooled results of the
replication cohort.
Hepatocyte Growth Factor
Hepatocyte growth factor (HGF) is an antifibrotic factor
involved in regenerating damaged tissue by inhibiting
fibrosis and promoting angiogenesis [35]. HGF seems to
be on the other side of the fibrotic mediator spectrum as
transforming growth factor-β and therefore might be
involved in regulating fibrosis as observed in SSc. A recent
Japanese study examined four SNPs within HGF and its
receptor c-met for a role in SSc or SSc clinical subset
pathogenesis. The authors did not find a difference in the
distribution of the alleles of HGF or c-met SNPs between
SSc patients and controls. Interestingly, they found the
HGF −1652 TT genotype significantly more frequently in
SSc patients with end-stage lung disease compared with
patients without that disease (41% vs 8%). This association
was confirmed in a relatively small replication study
consisting of 155 SSc patients. Compensating for the
relatively small replication cohort is a Kaplan-Meyer
survival analysis showing that HGF −1652 TT carriers
had a higher probability of developing end-stage lung
disease in time than did carriers of the CT or CC genotype.
In addition, the HGF promoter harboring the HGF −1652 T
allele displayed decreased transcriptional activity compared
with the promoter carrying the C allele, which was
investigated by a luciferase reporter assay. Electrophoretic
mobility shift assays unveiled the presence of a potential
negative transcriptional regulator specifically binding to the
HGF promoter and harboring the HGF −1652 T allele
[36￿]. Despite its small size, this study is of particular
interest because it describes a variant of the HGF gene
distinctively involved in the fibrosis observed in SSc and
shapes out its functional relevance. Moreover, the results
are analyzed and presented in a Kaplan-Meyer curve that
points out clinical relevance more clearly than plain tables.
CD226
CD226, encoding DNAX accessory molecule 1, is impor-
tant in monocyte extravasation and was recently found to
be a genetic risk factor for AID [37, 38]. This observation
prompted investigation of a possible association of the
CD226 rs763361 nonsynonymous polymorphism with SSc.
To this purpose, a discovery cohort of 991 SSc patients and
1,008 controls and a replication cohort of 999 SSc patients
and 634 controls from European Caucasian descent were
utilized. The CD226 rs763361 T allele was found to be
associated with SSc in the discovery and the replication
samples (OR, 1.22 [95% CI, 1.10–1.34]). In addition, the
CD226 TT risk genotype was associated with dcSSc (OR,
1.86 [95% CI, 1.42–2.43]), ATAs (OR, 1.82 [95% CI,
1.38–2.40]), and fibrosing alveolitis (OR, 1.61 [95% CI,
1.25–2.08]). To investigate the functional relevance of the





+, and natural killer
T
+ cells obtained from 21 healthy donors genotyped for
CD226, and rs763361 was measured. The polymorphism
did not result in a significant change of CD226 expression
among these different sets of T cells [39].
The results described above, together with previously
described findings, might imply that the genetic back-
ground is exactly similar to that of other AIDs or the
idiopathic form of the SSc complication. However,
although it is undeniable that there is a large resemblance
between the genetic backgrounds of AIDs, some recently
published studies also point out genes previously associated
with AID that are not associated with SSc. This was true for
the SLE-associated genes CD89, FCGR2A, FCGR3A,
ITGAM, ITGAX,a n dCD58 [40–42]. In addition, a
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familiar hypertension and situated in the SLC6A4 gene
was not found to be associated with SSc-related PAH [43].
Finally, some potential genetic defects involved in SSc
pathogenic events were discarded, including the MMP2,
MMP9, and MMP14 genes [44]. These studies, if well-
performed and well-powered, are important because they
carve out the differences between AIDs more explicitly.
Genome-Wide Association Studies
Before 2010, two genome-wide association studies (GWAS)
were published addressing genetic susceptibility to SSc in a
non–hypothesis-driven manner. Although very relevant at
the time, they were premature considering the current
standards for marker resolution and patient and control
numbers. The first study utilized 400 markers and targeted
20 Choctaw patients with SSc and 76 matched controls [45].
The second (Korean) GWAS used an efficient number of
500,568 SNP markers but included only 137 SSc patients
and 564 controls. Unfortunately, the identified risk factors
for SSc were not replicated in a large US cohort.
Noteworthy, SNPs in genes previously associated with
SSc, including the aforementioned PTPN22, showed low
P values but failed to reach genome-wide significance [46].
In 2010, however, a large and robust GWAS was published.
This study included 2,296 SSc patients and 5,171 healthy
controls originating from The Netherlands, Germany,
Spain, and the United States. Different sets of markers
were used that ranged in density from 308,349–488,793
SNPs. This study adjusted for multiple testing by regarding
the genome-wide significance threshold (P≤5×10
-7) as the
limit for significance. The strongest association was
observed at the 6p21 locus in the midst of the major
histocompatibility complex region. At this region,
rs6457617, situated in HLA*DQB1, showed the strongest
association. In addition, five non-HLA loci showed
genome-wide significance: TNPO3/IRF5 region in 7q32,
STAT4 in 2q32, CD247 in 1q22-23, CDH7 in 18q22, and
EXOC2/IRF4 near 6p25. These results further establish
STAT4 and IRF5 as genetic risk factors for SSc. To verify
the novel findings, a case–control set comprising 2,753 SSc
patients and 4,569 controls was genotyped for the 3 not
previously described variants. Two SNPs identified in the
discovery cohort in the EXOC2/IRF4 and CDH7 regions
were not replicated in the validation cohort. However, the
initial association with rs2056626 in the CD247 gene was
replicated [47￿]. CD247 is of particular interest considering
it has an important role in the immune system by encoding
the T-cell receptor zeta subunit, which is a component of
the T-cell receptor complex; this gene has also been
associated with susceptibility to SLE previously [48]. The
association of CD247 was recently replicated independently
in a French Caucasian population consisting of 1,031 SSc
patients and 1,014 healthy controls [49].
A follow-up study exploiting the above-mentioned
GWAS data focused on determining genetic components
contributing to lcSSc, dcSSc, ACA positivity, and ATA
positivity. To this purpose, a meta-analysis was conducted
in 4 cohorts comprising 2,296 SSc patients and 5,171
healthy controls. Subsequently, 18 polymorphisms with
a P value lower than 1×10
-5—7i nt h el c S S cs u b t y p e ,5i n
t h ed c S S cs u b t y p e ,2i nA C Ap o s i t i v e s ,a n d4i nA T A
positives—were further tested in 9 independent cohorts
made up of an additional 3,175 SSc patients and 4,971
controls. Overall analysis revealed one variant in the
interferon regulatory factor 8 (IRF8) gene (rs11642873) to
be associated with lcSSc at genome-wide significance.
Variants in the growth factor receptor–bound protein 10
(GRB10) and sex determining region Y-box 5 (SOX5)
were just below the genome-wide significance threshold
associated with lcSSc and ACA-positive subgroups,
respectively (Table 1). Intriguingly, the authors proposed
a model of IRF8 and SOX5 affecting the formation of
extracellular matrix through collagen, type II, α1i nt h e
skin and other organs of SSc patients. Furthermore, this
study revealed genome-wide significant results in the
HLA-DQB1 locus with ACA-positive (OR, 2.48), in the
HLA-DPA1/B1 loci with ATA-positive (OR, 8.84), and in
NOTCH4 with ACA-positive (OR, 0.55) and ATA-
positive (OR, 0.54). This study is of particular interest
because it indicates that the heterogeneity of SSc pheno-
types is likely to be the reflection of a different genetic
foundation [50￿].
Very recently, the fourth GWAS was published that used
a high-resolution marker set comparable to that of the
previous study (~500,000 markers). The study used a two-
step approach; the first step consisted of a GWAS and was
conducted in a French cohort consisting of 564 cases and
1,776 controls. Although only 1 SNP showed genome-wide
significance, again in the HLA*DQB1 region, the authors
validated 20 SNPs (the top 17 significant SNPs and 3
previously associated SNPs) in a replication cohort of 1,682
SSc cases and 3,926 controls. Follow-up of the top 17
SNPs revealed associations at PSORS1C1 (HLA region),
TNIP1, and ras homolog gene family, member B (RHOB)
loci (Table 1). Furthermore, the associations of previously
identified candidate loci STAT4, IRF5, and CD247 were
substantiated. This study also addressed the functional
relevance of the findings by investigating the TNIP1 gene
and protein expression. TNIP1 was expressed at a lower
level in both SSc lesional skin tissue and cultured dermal
fibroblasts from SSc patients based on genotype. Intrigu-
ingly, TNIP1 showed in vitro inhibitory effects on cytokine-
induced collagen production. Although this study presents
16 Curr Rheumatol Rep (2012) 14:11–21novel and interesting candidate loci, it must be noted that
only one locus reached genome-wide significance initially.
The other loci became highly significant after pooling of
the first and second step but are, strictly speaking, not
significant yet in the initial French GWAS. These loci
not being identified from the first step may be a power
problem resulting from the relatively low number of
patients included in the genome-wide association step. In
addition, the study does not indicate if there is an
overlap between cohorts used for previous studies
identifying SSc susceptibility genes STAT4, IRF5, and
CD247 and the ones used in this study for replication,
which would be welcome in order to place these results in
the correct perspective [51].
Gene–Gene Interaction Studies
As discussed in the previous sections, a large number of
genetic variants seem to be involved in SSc susceptibility
and pathogenesis. These associated genes all have a very
modest but reproducible effect on susceptibility throughout
populations. In line with the paradigm of multifactorial
diseases, one would expect to be at higher risk of SSc
when harboring more susceptibility variants. Not until
recently did genetic research in the field of SSc start to
combine genetic data to determine whether some variants
together formed an additive risk for SSc susceptibility.
An additional thought that justifies these attempts is that
many SSc candidate genes map to the same biological
pathways [5].
The first successful attempt showed that STAT4
(rs7574865) and IRF5 (rs2004640) variants form an
additive risk for development of SSc and interstitial lung
disease [15]. After this first study, this research group
repeated the analysis including the BANK1 polymorphisms
and was able to display an additive effect with regard to
diffuse SSc susceptibility [52]. In a subsequent analysis,
they added an NLRP1 polymorphism to the list of variants
interacting with STAT4 and IRF5 [34]. In contrast, the SSc-
associated BLK region had an additive effect with BANK1
in the dcSSc subset [53]. An American study showed that
the STAT4 polymorphism was predominantly enriched in
SSc patients who carried the CC genotype at TBX21
rs11650354 [16]. Next to this, an interesting study was
published in 2010 describing a three-factor model comprising
two SNPs: IL-6 -174 C>G and the IL-2 -330 G>T, and the
HLA-B*3501 allele that was predictive of the occurrence of
digital ulcers in 200 Italian SSc patients [54￿].
These initial studies on interactions of susceptibility
genes look promising, but they still display only a small
proportion of the risk of development of SSc. The most
promising findings of gene–gene interactions playing a
role likely will come forward from genome-wide interac-
tion analysis. However, this kind of analysis is currently
hampered by a lack of computational power and robust
statistical methods.
Conclusions
This review aimed to provide an overview of the genetic
research that has been conducted in the field of SSc in the
past year. When reviewing this research, it becomes
apparent that exciting progress has been made in several
aspects of genetic research, including family-based studies,
candidate studies, and (most noteworthy) GWAS. These
observations together further substantiate the role of genetic
susceptibility in SSc.
Although association studies of SSc in previous years
mainly addressed genetic variants emerging from observa-
tions in other AIDs, last year, investigators turned with an
increasing frequency toward genes involved in distinct
biological processes by function that were possibly
involved in SSc pathogenesis. This, however, yielded
positive and negative results, with on one hand associations
of NLRP1 and KCNA5 with PAH, and on the other hand no
associations with fibrosis-related MMP genes. An attractive
future perspective is the increasing number of multicenter
initiatives focusing on unraveling the genetic background
of SSc. This has the potential to lead to large genetic
consortia with more than 10,000 SSc DNA samples, well-
powered to discover even smaller genetic effects. The
single most important step forward is the large and robust
Fig. 1 Graphical representation of the immunologic point of impact of
the newly discovered systemic sclerosis susceptibility genes. B—Bc e l l ;
DC—dendritic cell; EC—vascular endothelial cell; ECM—extracellular
matrix; FB—fibroblast; T—Tce ll ;T NF —tumor necrosis factor
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bility genes similar to other AIDs, including RA and SLE.
The challenge for the following years will be to identify
whether certain combinations of risk alleles can drive the
development of a particular AID, such as SSc, on a
genetically similar background. In parallel with this,
epigenetic research should focus on investigating the
connections between the genetically susceptible host and
the impact of environmental factors on expression of this
susceptible genotype. The observation that birth order is a
risk factor for SSc, reported last year, strongly hints in
this direction.
An important gap in our understanding of the
genetics involved in SSc is the lack of functional
validation of genetic findings in immune cells or
fibroblasts. Fortunately, this is being addressed more
and more. Adding this functional validation step to
candidate gene studies has become more mainstream in
the past year, which enables researchers dedicated to
investigating SSc pathogenesis on a cellular level to pick
interesting molecules more efficiently from genetics re-
search. This is of particular interest because the newly
discovered variants affect multiple immunologic processes
(Fig. 1). Another point, well-recognized as problematic in
genetic research, is the translation from bench to bedside
or, more precisely, the relevant clinical consequences of
carrying a genetic variant that increases the risk of
developing SSc. This is slowly becoming more apparent
to researchers in the realm of SSc genetic research, as
complication risk analysis using follow-up data is pub-
lished at an increased rate. Ultimately, genetic risk factors
might be used to better predict the development of
scleroderma renal crisis, pulmonary hypertension, and
pulmonary fibrosis. This might enable rheumatologists
and other physicians to identify patients at risk early and
start preventive treatment or check-ups at a higher
frequency. A problematic subject in this aspect remains
the low OR reported for genetic variants associated with
complication development. However, if the investigations
into applicable gene–gene interactions continue to expand
in the way they did last year, combinations of poly-
morphisms might be discovered that provide enough risk
to become clinical relevant for testing and a prelude to
preventive treatments in the upcoming years.
In summary, there has been a steep increase in
knowledge regarding the genetic background of SSc in
the past year. This knowledge together with previous
investigations forms a solid base for the next and most
important step: the translation of genetic findings to more
efficient patient care and therapeutic interventions.
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